Soluble TCR therapeutics targeting human leukocyte antigen Class II expression

Yellowstone Biosciences is focused on developing a new class of therapeutically targetable antigens that are frequently expressed in various cancers, particularly acute myeloid leukaemia (AML). The company leverages a proprietary biobank containing over 10,000 samples from AML patients, which includes a unique cohort of high-risk patients who have been cured through allogeneic stem cell transplantation. This extensive research enables Yellowstone to identify novel peptide antigens presented by HLA Class II molecules, which are crucial for the development of targeted therapies. The company aims to create therapeutic T-cell bispecific molecules that can selectively target these antigens, potentially leading to effective treatments that spare healthy cells while attacking tumor cells.

In addition to AML, Yellowstone plans to explore the application of its technology in other solid tumors that exhibit HLA Class II expression, such as ovarian cancer, non-small cell lung cancer, colorectal cancer, prostate cancer, breast cancer, renal cancer, and melanoma. By focusing on these frequently expressed antigens, Yellowstone aims to significantly improve patient outcomes in various cancer types, addressing a critical need in oncology where many patients still face poor prognoses. The company's innovative approach has the potential to transform cancer treatment paradigms by providing highly selective and effective therapeutic options.

United Kingdom

Yellowstone aims to unlock a new class of therapeutically targetable frequently expressed antigens with potential to significantly transform patient lives.

Spun out of the University of Oxford, Yellowstone is built around the pioneering research of Professor Paresh Vyas, a world-renowned scientific academic, key opinion leader and practising clinician with a specialist focus on acute myeloid leukaemia (AML).

The Company is headquartered in Oxford, UK, with backing from a leading FTSE 250 healthcare company, Syncona.

Yellowstone Biosciences

Company Details